Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thorac Cancer
Main Authors: Tang, Kejing, Jiang, Neng, Kuang, Yukun, He, Qiong, Li, Shuhua, Luo, Jiping, Jiang, Wenting, Chen, Yangshan, Sun, Yu, Chen, Lili, Chen, Yanyang, Zhu, Junfeng, Cui, Yongmei, Wan, Han, Ke, Zunfu
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2018
Teme:
Case Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://ncbi.nlm.nih.gov/pubmed/30521113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12927
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki